BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2024 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Wednesday, September 4th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $0.71 for the quarter, up from their previous estimate of $0.50. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.40 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s Q4 2024 earnings at $0.71 EPS, FY2024 earnings at $2.66 EPS, Q1 2025 earnings at $0.49 EPS, Q2 2025 earnings at $0.83 EPS, Q3 2025 earnings at $0.84 EPS, Q4 2025 earnings at $0.84 EPS, FY2025 earnings at $3.01 EPS and FY2026 earnings at $5.19 EPS.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.39. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. The company had revenue of $712.03 million during the quarter, compared to analysts’ expectations of $660.51 million.
Read Our Latest Stock Analysis on BMRN
BioMarin Pharmaceutical Stock Performance
Shares of NASDAQ:BMRN opened at $84.33 on Monday. BioMarin Pharmaceutical has a 12-month low of $73.68 and a 12-month high of $99.56. The company’s 50 day moving average price is $86.57 and its two-hundred day moving average price is $84.97. The firm has a market cap of $16.01 billion, a PE ratio of 78.81, a PEG ratio of 1.02 and a beta of 0.31. The company has a quick ratio of 1.95, a current ratio of 3.05 and a debt-to-equity ratio of 0.11.
Institutional Investors Weigh In On BioMarin Pharmaceutical
Several hedge funds have recently added to or reduced their stakes in BMRN. AMI Asset Management Corp grew its position in shares of BioMarin Pharmaceutical by 51.9% in the 1st quarter. AMI Asset Management Corp now owns 346,189 shares of the biotechnology company’s stock valued at $30,236,000 after buying an additional 118,230 shares during the last quarter. ING Groep NV bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at approximately $20,248,000. Fisher Asset Management LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter valued at approximately $1,301,000. APG Asset Management US Inc. bought a new position in BioMarin Pharmaceutical during the 4th quarter worth approximately $3,462,000. Finally, Bridgewater Associates LP lifted its position in shares of BioMarin Pharmaceutical by 18.3% in the 4th quarter. Bridgewater Associates LP now owns 190,970 shares of the biotechnology company’s stock worth $18,413,000 after purchasing an additional 29,576 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading
- Five stocks we like better than BioMarin Pharmaceutical
- Buy P&G Now, Before It Sets A New All-Time High
- Why Block’s Key Components Make It a Solid Investment Choice
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.